Analysis of Profitability Ratios
Quarterly Data
Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Profitability Ratios (Summary)
Medtronic PLC, profitability ratios (quarterly data)
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
- Gross Profit Margin
- The gross profit margin experienced a decline from July 2020 through April 2021, reaching its lowest point around April 2020 at 63.85%. Following this dip, there is a gradual recovery that stabilizes near the 65% mark, with minor fluctuations observed through to April 2025. The margin generally holds between approximately 65% and 67.9% during the period after the initial drop, indicating relative stability in cost control and pricing after the early decline.
- Operating Profit Margin
- The operating profit margin demonstrated a notable decreasing trend from July 2020 (16.57%) to April 2021 (11.44%), reflecting a reduction in operational efficiency or increased operating expenses during this period. After this low point, the margin rebounded strongly, peaking at 19.37% by July 2022. Subsequently, the margin showed some volatility but maintained a range generally between 15.8% and 18%, signaling improved operating performance compared to the earlier periods.
- Net Profit Margin
- The net profit margin declined sharply between July 2020 (16.56%) and April 2021 (10.36%), mirroring the trend observed in the operating margin and suggesting adverse impacts on overall profitability. Following April 2021, the margin improved steadily, reaching a high of 16.75% in July 2022. After this peak, the margin again decreased, stabilizing around 12% to 14% up to April 2025, highlighting variability in net profitability but with partial recovery from earlier lows.
- Return on Equity (ROE)
- The ROE followed a downward trajectory from 9.44% in July 2020 to 5.7% in April 2020 before making a recovery that saw it rise near 9.88% in July 2022. Post July 2022, ROE fluctuated but generally stayed between 7% and 9%, indicating moderate recovery of shareholder returns with periodic declines likely reflecting volatility in net income or equity levels.
- Return on Assets (ROA)
- ROA declined from 5.28% in July 2020 to its lowest at 2.97% in April 2020, corresponding with operating and net margin trends. Following this trough, ROA gradually improved, reaching 5.79% by July 2022. Afterward, the metric demonstrated some stability, fluctuating between approximately 4% and 5.5%, suggesting consistent asset utilization efficiency post-recovery period.
Return on Sales
Return on Investment
Gross Profit Margin
Medtronic PLC, gross profit margin calculation (quarterly data)
| Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||
| Gross profit | 5,781) | 5,513) | 5,457) | 5,154) | 5,544) | 5,307) | 5,223) | 5,074) | 5,565) | 5,038) | 5,050) | 4,855) | 5,498) | 5,304) | 5,350) | 5,389) | 5,536) | 5,154) | 4,942) | 4,002) | 3,733) | 5,317) | 5,312) | 5,127) | |||||||
| Net sales | 8,927) | 8,292) | 8,403) | 7,915) | 8,589) | 8,089) | 7,984) | 7,702) | 8,544) | 7,727) | 7,585) | 7,371) | 8,089) | 7,763) | 7,847) | 7,987) | 8,188) | 7,775) | 7,647) | 6,507) | 5,997) | 7,717) | 7,706) | 7,493) | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||||
| Gross profit margin1 | 65.32% | 65.27% | 65.04% | 65.16% | 65.34% | 65.50% | 65.40% | 65.68% | 65.67% | 66.43% | 67.21% | 67.61% | 67.98% | 67.89% | 67.39% | 66.53% | 65.19% | 63.85% | 64.57% | 65.76% | 67.41% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 51.50% | 50.93% | 50.96% | 50.53% | 50.27% | 50.28% | 49.97% | 50.23% | 50.66% | 51.54% | 52.60% | 53.54% | 52.44% | 52.21% | 52.01% | 50.69% | 51.25% | 50.49% | — | — | — | |||||||
| CVS Health Corp. | — | — | — | 13.54% | 13.29% | 13.81% | 14.37% | 14.55% | 14.94% | 15.34% | 15.69% | 16.16% | 16.62% | 16.94% | 17.12% | 17.35% | 17.48% | 17.35% | 17.43% | 17.99% | 18.01% | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | 15.66% | 15.92% | 16.62% | 17.16% | 16.92% | 16.79% | 16.86% | 16.89% | 16.90% | 16.79% | 16.85% | 16.79% | 16.89% | 17.09% | 17.30% | 17.57% | 19.38% | 19.71% | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | 67.09% | 67.46% | 66.98% | 66.86% | 66.43% | 66.39% | 66.61% | 66.74% | 66.86% | 67.44% | 67.77% | 68.16% | 68.84% | 69.32% | 69.12% | 68.69% | 66.48% | 65.65% | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | 20.98% | 21.31% | 21.91% | 22.63% | 23.18% | 23.64% | 24.16% | 24.08% | 24.20% | 24.09% | 23.74% | 23.51% | 23.31% | 23.60% | 23.75% | 23.80% | 25.79% | 25.62% | — | — | — | |||||||
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q4 2025 Calculation
Gross profit margin = 100
× (Gross profitQ4 2025
+ Gross profitQ3 2025
+ Gross profitQ2 2025
+ Gross profitQ1 2025)
÷ (Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025
+ Net salesQ1 2025)
= 100 × (5,781 + 5,513 + 5,457 + 5,154)
÷ (8,927 + 8,292 + 8,403 + 7,915)
= 65.32%
2 Click competitor name to see calculations.
- Gross Profit Trends
- The gross profit displayed fluctuations over the analyzed periods. Initially, from July 2019 to January 2020, there was a steady increase from 5,127 million to 5,317 million US dollars. However, a significant drop occurred in April 2020, falling to 3,733 million. Following this low point, gross profit generally recovered with periodic variations, reaching a peak of 5,565 million in April 2023. Subsequent quarters saw some declines and increases, stabilizing around the 5,300 to 5,700 million range towards the latter periods, with the highest recorded in April 2025 at 5,781 million US dollars.
- Net Sales Patterns
- Net sales mirrored the gross profit's overall trajectory, showing strong growth with intermittent contractions. Starting at 7,493 million US dollars in July 2019, sales rose steadily until January 2020, then dropped sharply to 5,997 million in April 2020. After this trough, net sales rebounded consistently, reaching an apex of 8,589 million in April 2024. Subsequent quarters experienced minor fluctuations but generally remained above 7,900 million, indicating a sustained recovery and growth from the pandemic period downturn.
- Gross Profit Margin Stability
- The gross profit margin was not reported for the first three quarters but once available, it remained relatively stable. It fluctuated narrowly in a range between approximately 63.85% and 67.98%. Margins experienced a low in the range of 63.85% in April 2020, coinciding with the reduced gross profit and net sales at that time, and peaked near 68% in the mid-2022 period. Through the successive quarters, the margin sustained a modest downward trend but held steady around 65% in the latest reporting periods, highlighting a consistent cost structure and pricing strategy.
- Insights on Market and Operational Impact
- The sharp decline in both net sales and gross profit in April 2020 is notable and likely reflects significant market or operational disruptions during that quarter. The subsequent rebound and growth suggest effective recovery measures and market adaptation. The stability in gross profit margin over the years underscores consistent cost management despite external pressures. Overall, the financial figures reflect resilience and gradual growth following a period of volatility.
Operating Profit Margin
Medtronic PLC, operating profit margin calculation (quarterly data)
| Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||
| Operating profit | 1,436) | 1,646) | 1,595) | 1,278) | 1,053) | 1,483) | 1,340) | 1,268) | 1,564) | 1,392) | 1,404) | 1,125) | 1,671) | 1,659) | 1,563) | 859) | 1,604) | 1,277) | 930) | 673) | 316) | 1,639) | 1,351) | 1,485) | |||||||
| Net sales | 8,927) | 8,292) | 8,403) | 7,915) | 8,589) | 8,089) | 7,984) | 7,702) | 8,544) | 7,727) | 7,585) | 7,371) | 8,089) | 7,763) | 7,847) | 7,987) | 8,188) | 7,775) | 7,647) | 6,507) | 5,997) | 7,717) | 7,706) | 7,493) | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||||
| Operating profit margin1 | 17.76% | 16.78% | 16.39% | 15.82% | 15.89% | 17.50% | 17.41% | 17.83% | 17.56% | 18.17% | 19.02% | 19.37% | 18.15% | 17.89% | 16.68% | 14.78% | 14.89% | 11.44% | 12.77% | 14.25% | 16.57% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 16.84% | 16.27% | 16.24% | 15.92% | 15.76% | 16.15% | 15.02% | 15.23% | 16.77% | 19.16% | 20.95% | 22.42% | 20.73% | 19.56% | 20.04% | 18.46% | 17.97% | 15.48% | — | — | — | |||||||
| CVS Health Corp. | — | — | — | 2.55% | 2.30% | 2.59% | 3.42% | 3.49% | 3.85% | 4.04% | 1.88% | 2.33% | 2.41% | 2.02% | 4.35% | 4.39% | 4.54% | 4.75% | 4.93% | 5.19% | 5.19% | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | 4.07% | 4.16% | 4.55% | 4.76% | 4.64% | 4.47% | 4.58% | 4.96% | 4.99% | 4.94% | 5.01% | 5.07% | 5.10% | 5.15% | 4.91% | 3.68% | 4.83% | 4.97% | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | 28.20% | 28.12% | 26.24% | 25.79% | 25.26% | 24.80% | 24.66% | 24.34% | 24.21% | 25.35% | 27.05% | 28.48% | 30.69% | 31.89% | 32.55% | 31.27% | 26.01% | 24.09% | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | 8.27% | 8.17% | 8.28% | 8.40% | 8.58% | 8.80% | 8.86% | 8.83% | 8.87% | 8.83% | 8.65% | 8.32% | 8.19% | 8.40% | 7.91% | 7.73% | 9.24% | 8.76% | — | — | — | |||||||
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q4 2025 Calculation
Operating profit margin = 100
× (Operating profitQ4 2025
+ Operating profitQ3 2025
+ Operating profitQ2 2025
+ Operating profitQ1 2025)
÷ (Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025
+ Net salesQ1 2025)
= 100 × (1,436 + 1,646 + 1,595 + 1,278)
÷ (8,927 + 8,292 + 8,403 + 7,915)
= 17.76%
2 Click competitor name to see calculations.
- Operating Profit
- The operating profit demonstrates considerable volatility across the periods analyzed. Initially, the operating profit starts at a relatively high level but experiences a significant decline in April 2020, reaching a low point of 316 million USD. This drop coincides with an overall downturn in net sales during the same quarter. Following this low, operating profit progressively recovers over subsequent quarters, peaking around early 2022 with values exceeding 1600 million USD. However, after this peak, the operating profit again exhibits fluctuations, with intermittent decreases and rises, maintaining a general range between approximately 1100 million and 1600 million USD through to the last observed period in April 2025.
- Net Sales
- Net sales show a somewhat fluctuating yet generally upward trend over the examined timeline. After an initial drop during the April 2020 quarter, net sales begin to recover gradually, surpassing previous highs by mid-2021. Despite some quarterly variances, including a notable dip around mid-2022, the overall trajectory is upward, culminating in higher sales figures close to 8900 million USD by the end of the period in April 2025. This indicates resilience and growth in revenue streams despite intermittent periods of contraction.
- Operating Profit Margin
- The operating profit margin, available from April 2020 onwards, reflects an initial impact of reduced profitability during the early pandemic period, with margins starting at 16.57%. Subsequently, there is a general trend of margin improvement, peaking above 19% in mid-2022. After this peak, margins slightly decrease but remain relatively stable in the range of 15.8% to 17.8%, without returning to the lower margins seen at the pandemic's onset. This stabilization suggests enhanced operational efficiency and control over costs relative to revenue in the later periods.
- Overall Insights
- The data indicates a clear impact from the global environment around the early 2020 period, visibly affecting both sales and profitability. Recovery is evident across all metrics after this disruption, with net sales and operating profit gradually improving. While operating profit exhibits higher volatility compared to sales, the operating profit margin's recovery and subsequent stability underscore effective cost management and operational adjustments. The trends imply resilience in business performance and the ability to adapt to challenging conditions, with a generally improving financial health profile toward the most recent quarters.
Net Profit Margin
Medtronic PLC, net profit margin calculation (quarterly data)
| Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||
| Net income attributable to Medtronic | 1,056) | 1,294) | 1,270) | 1,042) | 654) | 1,322) | 909) | 791) | 1,180) | 1,222) | 427) | 929) | 1,485) | 1,480) | 1,311) | 763) | 1,360) | 1,270) | 489) | 487) | 646) | 1,915) | 1,364) | 864) | |||||||
| Net sales | 8,927) | 8,292) | 8,403) | 7,915) | 8,589) | 8,089) | 7,984) | 7,702) | 8,544) | 7,727) | 7,585) | 7,371) | 8,089) | 7,763) | 7,847) | 7,987) | 8,188) | 7,775) | 7,647) | 6,507) | 5,997) | 7,717) | 7,706) | 7,493) | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||||
| Net profit margin1 | 13.90% | 12.83% | 13.00% | 12.05% | 11.36% | 13.00% | 12.84% | 11.47% | 12.03% | 13.20% | 14.03% | 16.75% | 15.90% | 15.46% | 14.79% | 12.29% | 11.97% | 10.36% | 12.69% | 15.80% | 16.56% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 31.89% | 31.95% | 13.99% | 13.65% | 13.96% | 14.27% | 12.92% | 12.83% | 13.98% | 15.88% | 17.52% | 18.78% | 17.35% | 16.42% | 17.12% | 15.85% | 15.33% | 12.99% | — | — | — | |||||||
| CVS Health Corp. | — | — | — | 1.40% | 1.24% | 1.37% | 1.99% | 2.04% | 2.34% | 2.48% | 0.86% | 1.20% | 1.29% | 1.00% | 2.66% | 2.68% | 2.72% | 2.67% | 2.60% | 2.74% | 2.68% | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | 3.26% | 3.41% | 3.72% | 3.93% | 3.66% | 3.52% | 3.63% | 3.89% | 3.89% | 3.87% | 4.09% | 4.13% | 4.37% | 4.46% | 4.17% | 3.32% | 3.82% | 3.78% | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | 28.41% | 27.81% | 28.51% | 27.65% | 27.16% | 25.24% | 22.14% | 21.38% | 20.40% | 21.25% | 22.52% | 24.05% | 27.84% | 29.85% | 30.78% | 31.43% | 25.78% | 24.33% | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | 5.46% | 3.65% | 3.68% | 3.70% | 4.09% | 6.09% | 6.09% | 6.11% | 6.21% | 6.25% | 6.21% | 5.99% | 5.91% | 6.06% | 5.56% | 5.37% | 6.46% | 6.03% | — | — | — | |||||||
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q4 2025 Calculation
Net profit margin = 100
× (Net income attributable to MedtronicQ4 2025
+ Net income attributable to MedtronicQ3 2025
+ Net income attributable to MedtronicQ2 2025
+ Net income attributable to MedtronicQ1 2025)
÷ (Net salesQ4 2025
+ Net salesQ3 2025
+ Net salesQ2 2025
+ Net salesQ1 2025)
= 100 × (1,056 + 1,294 + 1,270 + 1,042)
÷ (8,927 + 8,292 + 8,403 + 7,915)
= 13.90%
2 Click competitor name to see calculations.
- Net Income Attributable to Medtronic
-
The net income demonstrates variability across the reported quarters, with notable peaks and troughs. Initial data points show a rise from 864 million USD in mid-2019 to a peak of 1915 million USD in early 2020, followed by a sharp decline to 646 million USD the subsequent quarter, likely reflecting an external shock. After fluctuating through 2020, the net income recovers and stabilizes with moderate oscillations between approximately 763 million and 1485 million USD throughout 2021 and 2022. A decline occurs again in late 2022 with values around 427 million USD, then a recovery ensues with income rising to over 1300 million USD in early 2024, followed by a gradual decrease towards the end of the observed period, ending at 1056 million USD. Overall, the pattern reveals cyclical trends with intermittent significant dips and recoveries.
- Net Sales
-
Net sales show a more stable but mildly fluctuating trend over the quarters. Starting at 7493 million USD in mid-2019, there is a modest increase to approximately 7700-7800 million USD prior to early 2020. A sharp decrease to 5997 million USD is observed in spring 2020, possibly reflecting market disruptions. Following this trough, sales progressively recover and generally increase, reaching highs near 8544 million USD by mid-2023. Despite periods of slight decline or plateau, net sales maintain a general upward trajectory ending with 8927 million USD in spring 2025. This indicates steady growth in revenue after periods of volatility.
- Net Profit Margin
-
Net profit margin data is sparse for earlier periods but from mid-2020 onwards reveals a consistent range between approximately 10% and 16.7%. Margins show a decline from around 16.5% mid-2020 to a lower bound near 10.36% by early 2021, followed by recovery and fluctuation mostly within a 12-16% band through 2023. From late 2023 onwards, margins remain relatively stable, oscillating close to 13%, with a slight uptick at the end of the dataset to nearly 13.9%. These results suggest a generally healthy profitability relative to sales with some sensitivity to quarterly earnings fluctuations.
- Overall Insights
-
The financial data reveals a cyclical pattern with significant impact likely from external market conditions around early 2020, affecting both income and sales sharply. Post this period, the company demonstrates strong resilience with gradual recovery and growth in sales and fluctuating yet stable net income and profit margins. The profit margin stability relative to the fluctuations in net income and net sales indicates effective cost control and operational efficiency over time.
Return on Equity (ROE)
Medtronic PLC, ROE calculation (quarterly data)
| Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||
| Net income attributable to Medtronic | 1,056) | 1,294) | 1,270) | 1,042) | 654) | 1,322) | 909) | 791) | 1,180) | 1,222) | 427) | 929) | 1,485) | 1,480) | 1,311) | 763) | 1,360) | 1,270) | 489) | 487) | 646) | 1,915) | 1,364) | 864) | |||||||
| Shareholders’ equity | 48,024) | 49,387) | 48,494) | 47,947) | 50,214) | 51,792) | 51,460) | 51,178) | 51,483) | 51,441) | 51,880) | 52,672) | 52,551) | 52,542) | 51,991) | 51,486) | 51,428) | 50,758) | 50,164) | 50,296) | 50,737) | 51,808) | 50,578) | 50,363) | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||||
| ROE1 | 9.71% | 8.63% | 8.84% | 8.19% | 7.32% | 8.11% | 7.97% | 7.07% | 7.30% | 7.90% | 8.33% | 9.88% | 9.59% | 9.35% | 9.05% | 7.54% | 7.01% | 5.70% | 7.05% | 8.77% | 9.44% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 27.66% | 28.12% | 14.49% | 14.13% | 14.51% | 14.83% | 13.77% | 13.88% | 15.68% | 18.90% | 22.11% | 23.44% | 21.82% | 19.75% | 21.04% | 18.86% | 17.06% | 13.71% | — | — | — | |||||||
| CVS Health Corp. | — | — | — | 6.86% | 6.11% | 6.69% | 9.60% | 9.90% | 10.91% | 11.57% | 4.02% | 5.57% | 5.84% | 4.46% | 10.86% | 10.83% | 10.54% | 10.20% | 9.83% | 10.44% | 10.35% | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | 13.92% | 14.47% | 14.66% | 15.86% | 15.38% | 15.23% | 15.82% | 16.78% | 16.62% | 16.59% | 17.26% | 17.04% | 17.36% | 16.93% | 15.44% | 12.10% | 13.92% | 13.77% | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | 14.47% | 14.13% | 14.39% | 14.23% | 14.24% | 13.51% | 12.10% | 12.00% | 11.70% | 11.98% | 11.97% | 11.93% | 13.58% | 14.32% | 14.80% | 14.97% | 11.56% | 10.90% | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | 23.26% | 15.55% | 15.14% | 15.78% | 17.72% | 25.22% | 25.67% | 25.63% | 25.46% | 25.87% | 26.03% | 25.07% | 23.98% | 24.09% | 21.95% | 21.03% | 25.42% | 23.52% | — | — | — | |||||||
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q4 2025 Calculation
ROE = 100
× (Net income attributable to MedtronicQ4 2025
+ Net income attributable to MedtronicQ3 2025
+ Net income attributable to MedtronicQ2 2025
+ Net income attributable to MedtronicQ1 2025)
÷ Shareholders’ equity
= 100 × (1,056 + 1,294 + 1,270 + 1,042)
÷ 48,024 = 9.71%
2 Click competitor name to see calculations.
The analysis of the quarterly financial data reveals several key trends and observations over the reported periods. The net income attributable to the company exhibits noticeable variability with distinct peaks and troughs. After an initial increase reaching a high point early on, net income experienced a significant decline in mid-2020, likely reflecting external or operational challenges during that time. Subsequently, net income showed periods of recovery, with fluctuations that suggest a pattern of intermittent strengthening and weakening. Notably, some quarters demonstrated strong profitability, while others reflected modest or reduced earnings.
Shareholders’ equity remained relatively stable throughout the periods, with minor fluctuations but broadly maintaining a consistent level. This stability suggests that the company managed to preserve its equity base despite varying profit levels. A slow declining trend in equity can be observed toward the later quarters, which may warrant attention concerning capital retention or distribution policies.
The Return on Equity (ROE) data, available for the later time points, also indicates a generally stable profitability level relative to shareholders’ investment. ROE values fluctuated mostly between 5.7% and 9.88%, displaying periods of moderate decline followed by recoveries. The ROE remained in a mid-range level without extreme deviations, suggesting a consistent return performance relative to equity. The periods with lower ROE correspond to times of decreased net income, reinforcing the connection between profitability and shareholder returns.
- Net Income
- Displayed notable volatility with sharp decreases around mid-2020 followed by recoveries and recurrent fluctuations.
- Some quarters experienced strong earnings, while others showed reduced net income, indicating variable operational performance or external influences.
- Shareholders' Equity
- Maintained relative stability across all periods without substantial growth or depletion.
- Toward the later quarters, a slight downward trend in equity is apparent, which may have implications for future capital structure decisions.
- Return on Equity (ROE)
- Remained relatively stable in the mid to high single digits, with minor fluctuations consistent with changes in net income.
- The periods of dip in ROE correspond to reduced profitability, confirming the sensitivity of returns to earnings performance.
Return on Assets (ROA)
Medtronic PLC, ROA calculation (quarterly data)
| Apr 25, 2025 | Jan 24, 2025 | Oct 25, 2024 | Jul 26, 2024 | Apr 26, 2024 | Jan 26, 2024 | Oct 27, 2023 | Jul 28, 2023 | Apr 28, 2023 | Jan 27, 2023 | Oct 28, 2022 | Jul 29, 2022 | Apr 29, 2022 | Jan 28, 2022 | Oct 29, 2021 | Jul 30, 2021 | Apr 30, 2021 | Jan 29, 2021 | Oct 30, 2020 | Jul 31, 2020 | Apr 24, 2020 | Jan 24, 2020 | Oct 25, 2019 | Jul 26, 2019 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||||||||
| Net income attributable to Medtronic | 1,056) | 1,294) | 1,270) | 1,042) | 654) | 1,322) | 909) | 791) | 1,180) | 1,222) | 427) | 929) | 1,485) | 1,480) | 1,311) | 763) | 1,360) | 1,270) | 489) | 487) | 646) | 1,915) | 1,364) | 864) | |||||||
| Total assets | 91,680) | 89,973) | 90,042) | 89,749) | 89,981) | 90,836) | 90,087) | 90,776) | 90,948) | 94,134) | 93,241) | 89,914) | 90,981) | 91,804) | 91,756) | 91,802) | 93,083) | 97,270) | 95,886) | 93,906) | 90,689) | 92,822) | 91,053) | 91,268) | |||||||
| Profitability Ratio | |||||||||||||||||||||||||||||||
| ROA1 | 5.09% | 4.73% | 4.76% | 4.38% | 4.09% | 4.63% | 4.55% | 3.99% | 4.13% | 4.32% | 4.63% | 5.79% | 5.54% | 5.35% | 5.13% | 4.23% | 3.87% | 2.97% | 3.69% | 4.70% | 5.28% | — | — | — | |||||||
| Benchmarks | |||||||||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||||||||
| Abbott Laboratories | — | — | — | 16.58% | 16.46% | 7.76% | 7.61% | 7.77% | 7.82% | 7.16% | 7.04% | 7.87% | 9.31% | 10.84% | 11.53% | 10.44% | 9.40% | 9.82% | 8.70% | 7.86% | 6.20% | — | — | — | |||||||
| CVS Health Corp. | — | — | — | 2.07% | 1.82% | 1.99% | 2.85% | 2.93% | 3.34% | 3.42% | 1.17% | 1.66% | 1.82% | 1.36% | 3.55% | 3.43% | 3.39% | 3.23% | 3.12% | 3.22% | 3.11% | — | — | — | |||||||
| Elevance Health Inc. | — | — | — | 4.94% | 5.12% | 5.51% | 5.92% | 5.58% | 5.50% | 5.50% | 5.87% | 5.69% | 5.86% | 6.03% | 6.05% | 6.21% | 6.26% | 5.63% | 4.40% | 4.93% | 5.28% | — | — | — | |||||||
| Intuitive Surgical Inc. | — | — | — | 12.88% | 12.39% | 12.64% | 12.57% | 12.56% | 11.64% | 10.31% | 10.25% | 10.05% | 10.19% | 10.39% | 10.47% | 12.02% | 12.58% | 13.06% | 13.20% | 10.17% | 9.50% | — | — | — | |||||||
| UnitedHealth Group Inc. | — | — | — | 7.14% | 4.83% | 4.78% | 4.93% | 5.40% | 8.18% | 7.69% | 7.53% | 7.30% | 8.19% | 7.99% | 7.93% | 7.89% | 8.15% | 7.24% | 6.90% | 8.23% | 7.81% | — | — | — | |||||||
Based on: 10-K (reporting date: 2025-04-25), 10-Q (reporting date: 2025-01-24), 10-Q (reporting date: 2024-10-25), 10-Q (reporting date: 2024-07-26), 10-K (reporting date: 2024-04-26), 10-Q (reporting date: 2024-01-26), 10-Q (reporting date: 2023-10-27), 10-Q (reporting date: 2023-07-28), 10-K (reporting date: 2023-04-28), 10-Q (reporting date: 2023-01-27), 10-Q (reporting date: 2022-10-28), 10-Q (reporting date: 2022-07-29), 10-K (reporting date: 2022-04-29), 10-Q (reporting date: 2022-01-28), 10-Q (reporting date: 2021-10-29), 10-Q (reporting date: 2021-07-30), 10-K (reporting date: 2021-04-30), 10-Q (reporting date: 2021-01-29), 10-Q (reporting date: 2020-10-30), 10-Q (reporting date: 2020-07-31), 10-K (reporting date: 2020-04-24), 10-Q (reporting date: 2020-01-24), 10-Q (reporting date: 2019-10-25), 10-Q (reporting date: 2019-07-26).
1 Q4 2025 Calculation
ROA = 100
× (Net income attributable to MedtronicQ4 2025
+ Net income attributable to MedtronicQ3 2025
+ Net income attributable to MedtronicQ2 2025
+ Net income attributable to MedtronicQ1 2025)
÷ Total assets
= 100 × (1,056 + 1,294 + 1,270 + 1,042)
÷ 91,680 = 5.09%
2 Click competitor name to see calculations.
- Net Income Attributable to Medtronic (US$ in millions)
- The net income exhibits notable fluctuations over the observed periods. Initially, there is a significant increase from 864 million to a peak of 1915 million by January 24, 2020. This is followed by a marked decline to 487 million by July 31, 2020, reflecting a sharp contraction. Subsequently, net income generally recovers and stabilizes with intermittent peaks and troughs; notable peaks appear in January 2022 (1480 million) and January 2024 (1322 million). The latest figures towards January 24, 2025, indicate a net income of 1294 million, showing a moderate upward trend after several earlier fluctuations.
- Total Assets (US$ in millions)
- Total assets remain relatively stable throughout the periods with minor variations. Initial values hover around 91,000 to 93,000 million with some cyclical declines and recoveries. The highest asset value is observed at 97,270 million in January 29, 2021, followed by a gradual decline and relative stability around approximately 90,000 million from early 2022 onward. This suggests limited asset growth or contraction with an overall tendency toward maintaining a steady asset base.
- Return on Assets (ROA, %)
- Return on Assets data is available starting from the April 24, 2020 period, indicating a value of 5.28%. Over subsequent quarters, ROA fluctuates moderately within a range of approximately 2.97% to 5.79%. Peak ROA is seen around July 29, 2022 (5.79%), followed by a gradual decline to the lowest point of 3.99% in April 28, 2023. Thereafter, ROA recovers somewhat, reaching 5.09% by April 25, 2025. The trend suggests variability in asset efficiency but generally a stable capacity to generate returns on assets over time.
- Summary of Trends and Insights
- The financial performance as measured by net income shows a high degree of volatility, with significant expansions and contractions that may reflect external market conditions or operational changes. Despite this, the company's asset base remains comparatively stable, suggesting cautious asset management without aggressive expansion or divestiture. The ROA movements parallel some of the income fluctuations, implying changes in profitability relative to total assets. Overall, the data points to a period of recovery after an initial downturn, followed by consistent, moderate profitability and asset stability.